Results of the treatment with a combination of carboplatin and piroxicam in seven dogs with advanced non-tonsillar oral squamous cell carcinoma (SCC) were retrospectively analysed.
This multi-agent protocol was well tolerated by all dogs and resulted in a complete regression of the tumour without additional surgery in four of seven patients.
Additional surgery was necessary to remove a metastatic lymph node in one dog and residual tumour in a second dog, which achieved a partial response following medical therapy.
Median follow-up for all the dogs was 534 days, while the time-to-recurrence, time-to-progression and overall survival for this group of patients have not yet been reached.
Our study, although limited in number of animals, suggests that this multiagent approach is a useful treatment option for oral non-tonsillar SCC in dogs and warrants wider application.
Source: de Vos, J. P., Burm, A. G. D., Focker, A. P., Boschloo, H., Karsijns, M. & van der Waal, I. (2005): Piroxicam and carboplatin as a combination treatment of canine oral non-tonsillar squamous cell carcinoma: a pilot study and a literature review of a canine model of human head and neck squamous cell carcinoma. In: Veterinary and Comparative Oncology 3 (1), 16-24.
|
